Clinical trial
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1…
NCT00129259 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00129259 |
|---|---|
| Title | Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes |
| Official title | Phase II Multiple-Dose Treatment of New Onset Type 1 Diabetes Mellitus With Anti-CD3 mAb |
| Acronym | AbATE |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Biological, Dietary Supplement, Other |
| Interventions | Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation |
| Enrollment | 83 |
| Start date | Sep 1, 2005 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Aug 11, 2005 |
| Last update posted | May 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: